NanoViricides Inc (NNVC)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.12-2.61%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NNVC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers
NNVC — debt issuance
Dated 2026-07-30
Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 24, 2026, NanoViricides, Inc. (the “Company”) and a certain purchaser (the “Investor”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering (the “Offering”): (i) 2,416,339 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.53 per s…
Why it matters: Reducing cash burn shows progress in handling losses. This is a key goal for management.
Supportive ifCash burn in Q2 2026 is lower than -$1.93 million.
Worry ifCash burn in Q2 2026 is worse than -$1.93 million.
Why it matters: The recent debt issuance may affect investor confidence and the stock price. If the share price drops significantly, it could signal concerns about the company's financial health.
Worry ifShare price falls below $1.50, the offering price of the recent debt issuance.
Less concerning ifIf the share price goes above $1.75, it shows strong investor confidence after issuance.
Why it matters: A drop in sector growth could impact NanoViricides' performance. It may signal broader issues.
Worry ifSector revenue growth is below its median. This shows possible challenges.
Less concerning ifSector revenue growth is above median. This shows continued strength.
Why it matters: Updates on NV-387 are important for its future sales. Good news can help investors.
Supportive ifManagement will announce a big milestone in NV-387's clinical trials.
Worry ifManagement reports delays in NV-387's clinical development. This is a setback for the project.
Why it matters: The healthcare sector is slowing down. If it improves, it may help NanoViricides' stock performance.
Watch forHealthcare sector revenue growth is speeding up again. It is now above 9%.
Also watch forHealthcare sector revenue growth is slowing down. It is now below 9%.
Why it matters: The health care sector is in a growth phase. If revenue growth drops below its median, it may signal broader issues affecting NanoViricides.
Worry ifRevenue growth in the health care sector falls below its historical median.
Less concerning ifRevenue growth is still above the median. This shows the sector is strong.
Why it matters: High cash burn could signal ongoing financial distress. Investors may react negatively.
Worry ifQ3 cash burn was over $2.5M. This shows worse financial health.
Less concerning ifCash burn was under $2.5M. This shows better cost management.
Why it matters: More debt could indicate financial strain. It may affect investor confidence.
Worry ifThey announced more debt issuance beyond recent agreements.
Less concerning ifNo new debt announcements were made. This shows stable financing.
Why it matters: Smaller losses show better cash management and efficiency. This matters for how investors feel.
Supportive ifOperating losses decrease further from $2.03 million in 2026-Q3.
Worry ifOperating losses get worse or stay the same compared to earlier quarters.
Why it matters: The debt issuance could affect investor confidence and share price. A strong reaction may signal support for the company's strategy.
Watch forShare price increases by more than 10% within a month after the debt issuance.
Also watch forShare price decreases by more than 10% within a month after the debt issuance.
Why it matters: This offering is important for funding operations and growth. Finishing it shows financial strength.
Supportive ifThe offering will close around July 27, 2026.
Worry ifThe offering fails to close or is delayed beyond the expected date.
Why it matters: Improving losses and cash burn is key for financial health. Better numbers show good management.
Supportive ifOperating income will be less than negative $2 million next quarter.
Worry ifOperating income will get worse or stay above negative $2 million next quarter.
Why it matters: More capital raises help fund operations and growth. More offerings show management's focus on this plan.
Supportive ifAnother direct offering will be announced in the next quarter.
Worry ifNo new offerings are announced in the next quarter.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $765 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,813 loss on $10,000 · 58.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.